Introduction
Being curious about the unfamiliar members of the MHC family, the Carter team focused on MHC-II in this new study. Similar to their MHC-I study, they applied computational biology to data from the Cancer Genome Atlas (TCGA), which is a database established by the National Institutes of Health from genomic information from different human tumors of thousands of species. They scored MHC-II molecules in 5942 patient tumors for their ability to present 1018 cancer antigens in order to assess their CD4+ T cells.
These researchers found that an antigen that is well recognized by a human MHC-II is less likely to appear in his or her tumor than a mutation that is ignored by MHC-II. MHC-II reflects this more than MHC-I. However, the Carter team was surprised to find that unlike MHC-I, the ability of MHC-II to recognize antigen was independent of the age at which a person was diagnosed with cancer.
These researchers found that an antigen that is well recognized by a human MHC-II is less likely to appear in his or her tumor than a mutation that is ignored by MHC-II. MHC-II reflects this more than MHC-I. However, the Carter team was surprised to find that unlike MHC-I, the ability of MHC-II to recognize antigen was independent of the age at which a person was diagnosed with cancer.
Contact Info
Address:
45-16 Ramsey Road, Shirley, NY 11967, USA
Shirley, NY
11967
United States
Shirley, NY
11967
United States
Tel:
Website:
https://www.creative-peptides.com/product/mhc-peptides-tetramer-class-2-68.html
Offering
- Therapeutic Peptides APIs Peptide Inhibitors Tumor Antigen Derived Peptides Cosmetic Peptides Anti-aging Anti-pigmentation Eye Care Hair Growth Others
Hours of operation
| From | To | From | To | From | To | ||
|---|---|---|---|---|---|---|---|
| Monday | Open | ||||||
| Tuesday | Open | ||||||
| Wednesday | Open | ||||||
| Thursday | Open | ||||||
| Friday | Open | ||||||
| Saturday | Open | ||||||
| Sunday | Open | ||||||
